These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 27791463

  • 1. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
    Shang C, Lang B, Meng LR.
    Cancer Biol Ther; 2018 Feb 01; 19(2):113-119. PubMed ID: 27791463
    [Abstract] [Full Text] [Related]

  • 2. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W, Lei C, Yu Y, Liu S, Li T, Lin F, Fan X, Shen Y, Ding M, Tang Y, Ye X, Yang Y, Hu S.
    Clin Cancer Res; 2019 May 01; 25(9):2835-2847. PubMed ID: 30670492
    [Abstract] [Full Text] [Related]

  • 3. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
    Yu Y, Zhang M, Zhang X, Cai Q, Hong S, Jiang W, Xu C.
    J Hematol Oncol; 2014 May 06; 7():39. PubMed ID: 24886678
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
    Xu Y, Tong J, Ai Z, Wang J, Teng Y.
    J Obstet Gynaecol Res; 2012 Dec 06; 38(12):1358-66. PubMed ID: 22612393
    [Abstract] [Full Text] [Related]

  • 8. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
    Ji N, Yu JW, Ni XC, Wu JG, Wang SL, Jiang BJ.
    Tumour Biol; 2016 Nov 06; 37(11):14637-14651. PubMed ID: 27619680
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma.
    Dai G, Liu G, Zheng D, Song Q.
    Eur J Pharmacol; 2021 May 15; 899():174058. PubMed ID: 33757752
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.
    Cancer Chemother Pharmacol; 2013 May 15; 71(5):1315-23. PubMed ID: 23468082
    [Abstract] [Full Text] [Related]

  • 13. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
    Bi YL, Min M, Shen W, Liu Y.
    Tumour Biol; 2016 Nov 15; 37(11):15145-15155. PubMed ID: 27677287
    [Abstract] [Full Text] [Related]

  • 14. Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells.
    Quan XX, Hawk NV, Chen W, Coupar J, Lee SK, Petersen DW, Meltzer PS, Montemarano A, Braun M, Chen Z, Van Waes C.
    Mol Cancer Ther; 2018 Sep 15; 17(9):2034-2048. PubMed ID: 29959199
    [Abstract] [Full Text] [Related]

  • 15. Endometrial Cancer Spheres Show Cancer Stem Cells Phenotype and Preference for Oxidative Metabolism.
    Carvalho MJ, Laranjo M, Abrantes AM, Casalta-Lopes J, Sarmento-Santos D, Costa T, Serambeque B, Almeida N, Gonçalves T, Mamede C, Encarnação J, Oliveira R, Paiva A, de Carvalho R, Botelho F, Oliveira C.
    Pathol Oncol Res; 2019 Jul 15; 25(3):1163-1174. PubMed ID: 30499076
    [Abstract] [Full Text] [Related]

  • 16. STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.
    Liu L, Jiang H, Wang X, Wang X, Zou L.
    Biosci Rep; 2020 Apr 30; 40(4):. PubMed ID: 32239181
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z, Zhang SL, Hu X, Tam KY.
    Eur J Pharmacol; 2018 Nov 05; 838():41-52. PubMed ID: 30213498
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.
    Kokabu T, Mori T, Matsushima H, Yoriki K, Kataoka H, Tarumi Y, Kitawaki J.
    Cell Oncol (Dordr); 2019 Apr 05; 42(2):223-235. PubMed ID: 30706380
    [Abstract] [Full Text] [Related]

  • 19. Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
    Kunimasa K, Nagano T, Shimono Y, Dokuni R, Kiriu T, Tokunaga S, Tamura D, Yamamoto M, Tachihara M, Kobayashi K, Satouchi M, Nishimura Y.
    Cancer Sci; 2017 Jul 05; 108(7):1368-1377. PubMed ID: 28445002
    [Abstract] [Full Text] [Related]

  • 20. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.
    Cancer Res; 2006 Jan 01; 66(1):404-11. PubMed ID: 16397255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.